Cargando…

Expression of CMTM4 shows clinical significance in lung cancer

BACKGROUND: Human chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is implicated in the pathogenesis of immune, reproductive systems and various cancers. However, the expression and clinical significance of CMTM4 in lung cancer have not been identified. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xiaonian, Zhang, Shidong, Tan, Shengkui, Li, Di, Chen, Xiaoyi, Kong, Juan, Fu, Yuanyuan, Wang, Changming, Wen, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798101/ https://www.ncbi.nlm.nih.gov/pubmed/35117232 http://dx.doi.org/10.21037/tcr-20-1254

Ejemplares similares

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Zhang, Shidong, et al.
Publicado: (2020)

Retraction Note to: Correlations between chromobox homolog 8 and key factors of epithelial–mesenchymal transition in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2020)

Correlations between chromobox homolog 8 and key factors of epithelial–mesenchymal transition in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2019)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma
por: Zheng, Chuanjun, et al.
Publicado: (2022)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Expression and clinical significance of PcG-associated protein RYBP in hepatocellular carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2017)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
por: Chen, Zhi, et al.
Publicado: (2021)

Single Nucleotide Polymorphisms of CBX4 and CBX7 Decrease the Risk of Hepatocellular Carcinoma
por: Tan, Chao, et al.
Publicado: (2019)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

MARVEL domain containing CMTM4 affects CXCR4 trafficking
por: Bona, Alexandra, et al.
Publicado: (2022)

Overexpression and clinical significance of MYC-associated zinc finger protein in pancreatic carcinoma
por: Zhu, Xiaonian, et al.
Publicado: (2016)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer
por: Si, Jiahui, et al.
Publicado: (2017)

CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology
por: Knizkova, Daniela, et al.
Publicado: (2022)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders
por: Chen, Shu, et al.
Publicado: (2020)

MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4
por: Zhang, Hongxia, et al.
Publicado: (2015)

CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
por: Li, Ting, et al.
Publicado: (2015)

CMTM3 as a Potential New Immune Checkpoint Regulator
por: Shen, Qian, et al.
Publicado: (2022)

CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions
por: Chrifi, Ihsan, et al.
Publicado: (2018)

High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
por: Muranushi, Ryo, et al.
Publicado: (2021)

CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway
por: Wei, Li, et al.
Publicado: (2022)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
por: Su, Yu, et al.
Publicado: (2014)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Schwann-cell-derived CMTM6 restricts radial axonal growth
por: Elazar, Nimrod, et al.
Publicado: (2020)

Progressive axonopathy when oligodendrocytes lack the myelin protein CMTM5
por: Buscham, Tobias J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ngtapuuiq1pujvh111iujem16